Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new ...

Zepbound is the “superior” choice for people looking to shed a few pounds, at least compared to Novo Nordisk’s (NVO) Wegovy, ...

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...

Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...

Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...

Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a ...